EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore

Yanting Ouyang iD, Yi Ting Ng, Wei Wei Hong, Nicholas Graves

Therapeutic Advances in Medical Oncology · 2026-03 · 18

DOI: 10.1177/17588359261421557 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Therapeutic Advances in Medical Oncology, online erschienen am 25.03.2026. Verfasst von Yanting Ouyang und 3 weiteren Autor:innen. Beteiligte Einrichtung: Health Services Research & Population Health, Duke-NUS Medical School, Singapore, Singapore. Die Arbeit nennt 8 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

With major changes in effective drug prices, we updated our earlier cost-minimization analysis comparing home-based subcutaneous (SC) trastuzumab with outpatient intravenous (IV) trastuzumab for HER2-positive breast cancer in Singapore.

Objectives

To compare updated annual per-patient costs of home care SC versus outpatient IV trastuzumab.

Design

A cost-minimization analysis was performed.

Methods

We conducted a model-based cost-minimization analysis using micro-costing from a societal perspective, incorporating both direct and indirect costs. A Monte Carlo simulation was performed to account for parameter uncertainties.

Results

Annual per-patient cost was S$21,790 (95% uncertainty interval (UI): S$19,662–23,922) for home care versus S$6949 (95% UI: S$5347–10,782) for outpatient care, representing a 214% increase. While service delivery (manpower, facility, consumables) and productivity loss remained cheaper in home care, drug cost is the dominant factor of overall expenditure in trastuzumab delivery.

Conclusion

At current drug prices, outpatient IV trastuzumab administration is the cost-saving option, compared with home care SC trastuzumab.

Schlagwörter

Stichwörter der Autor:innen

HER2-targeted therapybreast cancercost-effectiveness analysissubcutaneous trastuzumabtrastuzumab cost

Autor:innen und Institutionen

  • Health Services Research & Population Health, Duke-NUS Medical School, Singapore, Singapore.
  • Office for Service Transformation, SingHealth, Singapore, Singapore.
  • Health Services Research & Population Health, Duke-NUS Medical School, Singapore 168582, Singapore.

ORCID-Profile: Yanting Ouyang

Zitieren

APA

Ouyang, Y., Ng, Y. T., Hong, W. W., & Graves, N. (2026). Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore. Therapeutic Advances in Medical Oncology, 18. https://doi.org/10.1177/17588359261421557

Vancouver

Ouyang Y, Ng YT, Hong WW, Graves N. Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore. Therapeutic Advances in Medical Oncology. 2026;18. doi:10.1177/17588359261421557

BibTeX
@article{Ouyang2026,
  author = {Ouyang, Yanting and Ng, Yi Ting and Hong, Wei Wei and Graves, Nicholas},
  title = {Updated cost comparison of home care subcutaneous versus outpatient intravenous trastuzumab for HER2-positive breast cancer in Singapore},
  journal = {Therapeutic Advances in Medical Oncology},
  year = {2026},
  volume = {18},
  doi = {10.1177/17588359261421557}
}
Kostenlos starten →